NTLA Intellia Therapeutics Inc
Company Analysis
Latest News
Intellia Reports 87% Drop in HAE Attacks, Meeting Phase 3 Endpoints
Intellia Therapeutics announced positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema (HAE). The European Academy...
🔴 Intellia Therapeutics Inc is trading 5% down today on post-earnings weakness and dilution concerns
Intellia Therapeutics Inc is trading about 5% down today around the mid-$12s, extending a decline following its recent quarterly update and equity...
🔴 Intellia Therapeutics Inc is trading 5.1% down today amid post-earnings repositioning and dilution concerns
Intellia Therapeutics Inc is trading 5.1% down at $12.80 as investors continue to reassess the company's fundamentals following recent financial results and...
🔴 Intellia Therapeutics Inc is trading 10.51% down today as investors take profits amid broader market weakness and cash-burn concerns
Intellia Therapeutics Inc is trading at $13.20 (-10.51%) as investors lock in gains following a recent rally, while broader market pressure and cash-burn risks...
🔴 Intellia Therapeutics Inc is trading 8.6% down today on profit-taking and renewed focus on cash burn and dilution
Intellia Therapeutics Inc is trading at $13.47 (8.6% down) as investors lock in profits following yesterday’s 13% surge and shift focus back to the company's...
Intellia Pops 13.5% on Earnings-Beat Signal — But Can a Pre-Revenue Biotech Justify Its $1.8 Billion Price Tag?
Shares of Intellia Therapeutics surged 13.5% to $14.77 after a Zacks research note flagged the CRISPR gene-editing firm as statistically likely to beat Wall...
🟢 Intellia Therapeutics Inc is trading 13.5% up today on bullish research and expected EPS beat
Intellia Therapeutics Inc is trading 13.5% up today at $14.77 as investors react to fresh bullish research from Zacks ahead of the company's upcoming earnings...